Compare Nu Holdings Ltd (NU) vs Summit Therapeutics Inc (SMMT) Price & Performance

NU Holdings (NU) trades at $15.92, up 2.18% with bullish technical signals from moving averages. The company demonstrates strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income reaching $2.9B. Recent news highlights acquisition speculation around Monzo and Goldman Sachs' bullish stance, though the stock remains volatile amid mixed earnings performance with two misses and one beat in recent quarters.

The outlook remains positive with 56.5% analyst buy ratings and a $16.53 consensus target, though risks include credit concentration (85% customer concentration in Brazil) and rising delinquencies. The stock trades near resistance at $16 with RSI at 91 suggesting overbought conditions, requiring careful entry timing despite strong growth fundamentals.

Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.

The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.